Defeating malaria together

Interviews

  • PhD student, Kilimanjaro Christian Medical University College & Kilimanjaro Clinical Research institute

    Tanzania (2015)

  • Post doc Researcher, Makerere University School of Public Health

    Kampala, Uganda (2015)

  • Researcher, Department of Epidemiology and Medical Statistics, University of Ibadan

    Ibadan, Nigeria (2015)

  • Dr David Reddy, CEO, MMV

    David Reddy speaks with Camilla Burkot of the Development Policy Centre, about MMV's role in tackling malaria. (2015)

  • Dr David Reddy, CEO, MMV

    David Reddy speaks with Marcus Papadopoulos of Politics First magazine, about the successes scored against malaria and the new challenges emerging in this fight. (2015)

  • Dr Martin Casapia Asociación Civil Selva Amazónica (ACSA), Iquitos, Peru

    DSM265 is a triazolopyrimidine-based highly selective inhibitor of Plasmodium’s dihydroorotate dehydrogenase (DHODH), a key enzyme for the parasite’s survival. Dr Martin Casapia Asociación Civil Selva Amazónica (ACSA), Iquitos, Peru; Co-Investigator for the DSM265 phase IIa trial tells us more about this promising compound. (2015)

  • Dr Paul Willis, Director, Drug Discovery & Dr Lidiya Bebrevska, Associate Director, Translational Medicine, MMV

    DDD498 has potent activity against multiple stages of the malaria parasite’s lifecycle, giving it the potential to cure and stop the spread of the disease as well as protect people, all in a single-exposure. Dr Paul Willis and Dr Lidiya Bebrevska discuss recent progress and next steps. (2014)

  • Prof. Ian Gilbert, Head of Chemistry & Dr Kevin Read, Head of Drug Metabolism and Pharmacokinetics, University of Dundee, UK

    DDD498 has potent activity against multiple stages of the malaria parasite’s lifecycle, giving it the potential to cure and stop the spread of the disease as well as protect people, all in a single-exposure. Prof. Ian Gilbert and Dr Kevin Read explain how the discovery was made and their experience of working with MMV. (2014)

  • Adam Aspinall, Director, Product Strategy & Management, MMV

    MMV has become part of the ACCESS-SMC consortium, which is supporting the implementation and scale-up of SMC in the Sahel region. Adam Aspinall, Director, Product Strategy & Management explains the role of MMV and the implementing partners. (2014)

  • Penny Grewal Daumerie, MMV’s Director, Access and Delivery & Richard Rankin, Global Marketing Director, Infectious Diseases, GSK

    Tafenoquine is in phase III development with GSK. The aim is to investigate its potential as a single-exposure medicine to prevent the relapse of P. vivax malaria. MMV's Penny Grewal Daumerie explains the excitement around the new medicine and GSK's Richard Rankin speaks about the key challenges that must be overcome. (2014)

  • Dr Jetsumon Sattabongkot Head of the Mahidol Vivax Research Unit

    A team of researchers from Mahidol University, Thailand, has developed a P. vivax ‘hypnozoite’ cell-based in vitro assay able to screen up to 150 compounds a year. Dr Jetsumon Sattabongkot explains how the assay works, what it reveals and what lies ahead. (2014)

  • Dr Didier Ménard, Head, Malaria Molecular Epidemiology Unit, Institut Pasteur, Cambodia

    Dr Didier Ménard and his team have developed an in vitro assay to enable in-development antimalarials to be tested against the most resistant strains of parasite we know of today. Building on this work the team was also able to identify a molecular marker to identify artemisinin-resistant parasites, which is now being used to map artemisinin resistance globally. He explains why drug resistance is such a problem, how the assay works and what it has told us so far. (2014)

  • Dr Janneth Rodrigues, Insectary Supervisor at GSK-Tres Cantos

    Several of the molecules progressing through clinical development and translational research have demonstrated that they can kill the sexual stages or the gametocytes in vitro. Dr Janneth Rodrigues explains how a Standard Membrane Feeding Assay has shown that many of these molecules also have the potential to block the transmission of malaria in the laboratory. (2014)

  • Masahiko Koike, Director, Pharmaceutical Technology R&D Laboratories, Takeda

    Takeda recognized the urgent need to contribute to research in the field of infectious diseases, such as malaria. Masahiko Koike explains how the company is contributing to two exciting antimalarial drug projects and what it’s like to work with MMV. (2014)

  • Dr Elizabeth Winzeler, University of California, San Diego

    Medicines currently used to protect vulnerable populations are becoming less effective as the parasite develops resistance; they are also often not well tolerated. We need to develop tools and screen compounds to identify novel molecules with prophylactic activity. Dr Elizabeth Winzeler talks about the importance of continuing the hunt for new molecules and the collaboration with MMV. (2014)

  • Prof Jean Louis Ndiaye, Cheikh Anta Diop University of Dakar, Senegal

    Cheikh Anta Diop University of Dakar, Senegal, conducted a pilot study from 2011 to 2012 combining SMC with home management of malaria. Prof Jean Louis Ndiaye explains the challenges and the potential impact of SMC. (2013)

  • Dr Yusuf Hamied, CEO of Cipla & Mr Mohan Kumar CEO of Strides Arcolab

    WHO recommends the use of rectal artesunate as a pre-referral intervention for severe malaria. This option can substantially reduce the risk of death or disability, buying time for patients to be referred to centres that can provide recommended treatment. Dr Yusuf Hamied talks about getting involved in developing an rectal artesunate product and Mr Mohan Kumar explains how Strides will make a prequalified product widely available. (2014)

  • Matthew Chico, London School of Hygiene & Tropical Medicine

    (2014)

  • Dr Phumla Sinxadi, Clinical Pharmacologist at UCT & Prof. Karen Barnes, Clinical Pharmacologist at UCT

    MMV048 is a novel antimalarial compound from the aminopyridine class, and the first new medicine to be discovered by an African-led team. Dr Phumla Sinxadi explains how MMV048 is progressing and Prof. Karen Barnes describes why the compound and development programme are unique. (2014)

  • Rita Merino, Project Leader, Sanofi

    OZ439 is in phase IIb combination studies with piperaquine (PQP) as a single-exposure cure in partnership with Sanofi. Rita Merino, OZ439/ 4-aminoquinoline Project Leader at Sanofi, explains the challenges in the development of this next generation medicine and what it’s like to work with MMV. (2014)

  • Dr Robert Wenslow, VP Business Development & Alex Chen, Chief Executive Officer, Crystal Pharmatech

    Crystal Pharmatech, a Contract Research Organisation based in China, offer their expertise to MMV at a “not-for-profit” price. Dr Robert Wenslow, and Alex Chen explain why they work with MMV and what they have to offer. (2014)

  • Dr Queen Dube, Paediatrician, Queen Elizabeth Central Hospital, Blantyre, Malawi

    Dr Queen Dube, Paediatrician, Queen Elizabeth Central Hospital, Blantyre, Malawi, explains the malaria burden in Malawi and the ideal medicine to treat it. (2014)

  • Dr David Reddy, CEO, MMV

    David Reddy speaks with International Innovation and lays out MMV's ambitious short-term goals, and outlines the projects that are bringing new antimalarial drugs to those most in need. (2014)

  • Dr Isabelle Borghini-Fuhrer Director, Product Development, MMV

    Isabelle explains to International Innovation how MMV and partners are working to develop Pyramax®, a combination treatment of two antimalarial drugs that is soon to be launched in several malaria-endemic countries as a new therapy. (2014)

  • Dr David Reddy, CEO, MMV

    Today, malaria continues to kill over 600'000 people each year. Dr David Reddy explains how MMV works to discover, develop and facilitate the delivery of new, effective and affordable antimalarial drugs that are saving lives. (2014)

  • Dr Didier Leroy, Director, Drug Discovery, MMV

    To reduce the overall burden of malaria we need to be able to stop transmission from person-to-person. Dr Didier Leroy explains the test cascade, developed by MMV and partners, to identify new and in-development molecules with transmission blocking activity. (2013)

  • Prof Sangeeta Bhatia, Director, Laboratory for Multiscale Regenerative Technologies, MIT

    A team led by Massachusetts Institute of Technology researchers has taken a major step towards developing a cost-effective P. vivax cell assay, by developing a system to grow liver tissue that can support the liver stage of both Plasmodium falciparum and P. vivax malaria. Prof Sangeeta Bhatia explains her interest in this area of research and how the system works. (2013)

  • Prof Ric Price, Menzies School of Health Research and Charles Darwin University; and the Centre for Tropical Medicine, University of Oxford

    Relapsing Plasmodium vivax malaria results in around 70–80 million clinical infections each year. Prof Ric Price discusses why P. vivax should be a research priority and what tools are needed in order to eradicate it. (2013)

  • Dr Marc Adamy, Director, Product Development, MMV

    MMV and partners are working to identify and develop molecules that are fast acting and have a long duration of action for combination into a single-dose cure and first-generation SERCaP. Dr Marc Adamy explains the strategy to accelerate the development of OZ439. (2013)

  • Dr Isabelle Borghini-Fuhrer Director, Product Development, MMV

    Children under the age of 5 years are the main victims of malaria, yet few antimalarial medicines have been developed with children’s needs in mind. Dr Isabelle Borghini-Fuhrer Director, Product Development, talks about the progress made and challenges of developing paediatric medicines. (2013)

  • Dr Jörg Möhrle, Head of Translational Medicine & Dr Weweka Kaszubska, Vice President, Head of Product Development, MMV

    Tafenoquine entered Phase III in April 2014, taking it closer to becoming the only new medicine approved for the treatment of relapsing malaria in over 60 years. Dr Jörg Möhrle & Dr Wiweka Kaszubska talk about the challenges, the partnership and what the future holds. (2013)

  • Dr Thomas Spangenberg, Research Scientist, MMV

    The Malaria Box was launched in response to the need for access to physical samples of molecules to initiate drug discovery programmes for malaria and neglected diseases. The Pathogen Box is modelled on the success of the Malaria Box. Dr Thomas Spangenberg tells us how the Malaria Box is being used today and what's in store for the Pathogen Box. (2013)

  • Research Fellow/ Lecturer, University of Ghana Medical School & Noguchi Memorial Institute for Medical Research, Ghana

    Age: 41

  • Dr Mat Todd, University of Sydney, Australia

    In 2011, MMV launched an Open Source Drug Discovery (OSDD) programme. The programme differs from traditional drug discovery, as all research is reported openly, online and in real-time, allowing the best and the brightest to contribute. Dr Mat Todd, University of Sydney, leads one of these projects. He explains how it works and what the future might hold for open science. (2013)

  • Prof. James McCarthy, Queensland Institute of Medical Research, Berghofer Medical Research Institute

    To help expedite the development of promising compounds, MMV is employing innovative new tools. Prof. James McCarthy explains how the Challenge Model is helping to accelerate antimalarial drug development. (2013)

  • Dr Kennan Marsh, Director, Experimental Sciences, AbbVie Inc. USA

    AbbVie, a research-based biopharmaceutical company, has been providing pro bono drug discovery resources and expertise to MMV since 2011. Dr Kennan Marsh, the interface between MMV and AbbVie, talks about the collaboration, compounds and the motivation to get involved. (2013)

  • PhD student, International Centre for Genetic Engineering and Biotechnology, India
    PhD student, International Centre for Genetic Engineering and Biotechnology, India

    Age: 28

  • PhD student, Jimma University, Ethiopia
    PhD student, Jimma University, Ethiopia

    Age: 40

  • PhD student, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya
    PhD student, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya

    Age: 28

  • PhD student, Senior Research Fellow, National Institute of Malaria Research, India
    PhD student, Senior Research Fellow, National Institute of Malaria Research, India

    Age: 29

  • Dr Philippe Lukanu Ngwala, General Reference Hospital, DRC

    There are around 5.6 million cases of severe malaria every year, leading to an estimated 627,000 deaths, mostly of children under 5 years of age. Dr Philippe Lukanu Ngwala, General Reference Hospital, Kimpese district, DRC, explains the advantages of using artesunate to treat severe malaria. (2013)

  • Dr Madan Mohan Pradhan, Deputy Director Health Services, NVBDCP, Ministry of Health & Family Welfare, Odisha

    The National Institute of Malaria Research and the National Vector Borne Disease Control Programme, with technical and financial support from MMV, are implementing the Comprehensive Case Management Programme in four districts of Odisha. Dr Madan Mohan Pradhan speaks about the roll-out of this programme. (2013)

  • Prof Abdoulaye Djimde, University of Science, Techniques and Technologies of Bamako, Mali

    To help gather evidence to guide the optimal and widespread use of new ACTs, MMV works with partners to study how they fare in the real world. Prof. Abdoulaye Djimde talks about the WANECAM trial and what it has revealed so far. (2013)

  • Dr Keziah Malm, National Malaria Control Progamme, Ghana

    Artemisinin-based combination therapies (ACTs) are the current WHO-recommended standard of care for uncomplicated malaria. Dr Keziah Malm provides insight into the real-world advantages of multiple first-line ACTs, which were first instituted in Ghana in 2007. (2013)

  • Senior Research Officer, Kenya Medical Research Institute-University of Minnesota Malaria Project, Kisumu, Kenya
    Senior Research Officer, Kenya Medical Research Institute-University of Minnesota Malaria Project, Kisumu, Kenya

    Age: 40 years

  • Junior researcher, Fundação Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
    Junior researcher, Fundação Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

    Age: 40

  • Post-doctoral Visiting Scientist, Tata Institute of Fundamental Research, Mumbai, Maharashtra, India
    Post-doctoral Visiting Scientist, Tata Institute of Fundamental Research, Mumbai, Maharashtra, India

    Age: 32

  • MPhil Student, Noguchi Memorial Institute for Medical Research at the University of Ghana
    MPhil Student, Noguchi Memorial Institute for Medical Research at the University of Ghana

    Age: 26

  • Dr Brice Campo, Associate Director, Drug Discovery, MMV

    Our goal to eradicate malaria cannot be achieved without new anti-relapse medicines. Dr Brice Campo explains the research challenges presented by P. vivax and MMV’s discovery strategy to stop the relapse. (2012)

  • Dr Michael Witty, Member of MMV's ESAC and Project Mentor

    With more than 30 years of pharmaceutical research experience, Dr Michael Witty talks about the support he provides to project MMV390048. (2012)

  • Dr Tanjore Balganesh, Project Head at India's OSDD Initiative

    MMV is working closely with India’s Open Source Drug Discovery malaria programme to investigate the most promising compound series, initially for blood-stage malaria. Dr Tanjore Balganesh explains how open source research is taking off in India. (2012)

  • Mark Baker, Associate Director, Translational Medicine, MMV

    Mark Baker, a clinical pharmacologist, explains two innovations that are enabling MMV to accelerate the collection and use of PK/PD data to speed the development of next-generation antimalarials. (2012)

  • Prof Azra C Ghani, Imperial College London, UK & Prof Fred Binka, Principal Investigator of INESS

    Mathematical modelling studies suggest that using multiple first-line ACTs could yield better clinical outcomes than deploying a single ACT nationwide particularly when drug resistance or treatment failures emerge. Prof. Azra Ghani and Prof. Fred Binka discuss mathematical modelling and how gathering evidence can improve malaria treatment. (2012)

  • Prof. Kelly Chibale, Cape Town Drug Discovery and Development Centre (H3-D), South Africa

    With our sights firmly set on malaria elimination/ eradication, MMV’s discovery work is focused on the need for novel medicines to treat relapsing malaria and block transmission. Prof. Chibale talks about his work to discover and optimize new compounds to help populate MMV’s antimalarial drug pipeline. (2011)

  • Prof. Olugbenga A Mokuolu, Centre for International Education, University of Ilorin, Nigeria

    In 2011 the WHO revised its Standard Treatment Guidelines to recommend artesunate injection as the preferred treatment for severe malaria. Prof. Olugbenga A Mokuolu explains how the guideline change was made in Nigeria and what impact it has had. (2011)

  • Dr Fiona Macintyre, Associate Director, Translational Medicine, MMV

    While ACTs are available and access to them is improving, MMV cannot rest on its laurels, but must continue to innovate and develop better medicines for uncomplicated malaria. Dr Fiona Macintyre tells us about the development plan for OZ439. (2011)

  • Dr Stephan Duparc, Chief Medical Officer, MMV

    Monitoring post-approval drug safety has become a matter of increasing importance, as it enables us to maximize the safe use of registered medicines. Dr Stephan Duparc explains what pharmacovigilance means for MMV. (2011)

  • Prof. Vicky Avery, Griffith University, Australia

    In an infected patient a small proportion of parasites form gametocytes, the sexual form of the parasite. It is these gametocytes, taken up by the mosquito when she feeds, that ultimately allow the parasite to infect the next person. Prof. Vicky Avery talks about her work to develop a new late-stage gametocyte assay to identify compounds that could block the transmission of malaria. (2011)

  • Colonel Bagus Tjahjono, Indonesian Army Health Command, Jakarta

    Although primaquine is the only approved medicine for radical cure of relapsing malaria, very little is known about how well it works in combination with other medicines that treat the blood-stage infection. Colonel Bagus Tjahjono explains the need for further research on relapsing P. vivax malaria and its treatment. (2011)

  • Dr Alejandro Llanos, Universidad Peruana Cayetano Heredia, Lima, Peru

    The dormant liverstage form of P. vivax, which can reactivate without warning leading to the feverish symptoms of malaria, remains a challenge to treat. Dr Alejandro Llanos talks about why there is a need for new medicines to treat relapsing malaria in Peru. (2011)

  • Dr Jane Achan, Makerere University, Kampala, Uganda

    With the exception of Coartem® Dispersible, few antimalarial medicines have been specifically formulated for children. Dr Jane Achan explains the needs on the ground for doctors treating children suffering from malaria. (2011)

  • Dr Isabelle Borghini-Fuhrer Director, Clinical Development, MMV

    Few antimalarial medicines have been specifically formulated to provide children with age and weight-appropriate doses in a palatable form. Dr Isabelle Borghini-Fuhrer explains the challenges in the development of medicines for children and MMV’s strategy to overcome them. (2011)

  • Dr Elizabeth Juma, National Malaria Control Programme, Kenya

    Pregnancy lowers a woman’s immune response to infections and so she is four-times more likely to get malaria and twice as likely to die from it than another adult. Dr Elizabeth Juma explains the Kenya's approach to protecting pregnant women from malaria. (2011)

  • Mr Winna Shango, Ministry of Health and Social Welfare, Tanzania

    SMS for Life uses widely available SMS technology to record antimalarial stock levels at the point-of-care. Mr Winna Shango tells us how this programme is motivating health-care workers in Tanzania. (2011)

  • Mrs Esnet Mwape, Pharmaceutical Regulatory Authority, Zambia

    ACTs are currently the best medicines available to treat uncomplicated malaria but unfortunately many patients lack access to them. Ms Esnet Mwape explains how the medicinal products coming into Zambia are now better regulated. (2011)

  • Sigma-Tau, Italy

    In 2011 Eurartesim® was approved by the European Medicines Agency (EMA) – the first new European antimalarial medicine for over a decade. This is a huge achievement, and takes the medicine a step closer to the patients that so sorely need it. (2011)

  • Guilin Pharmaceutical, China

    Guilin Pharmaceutical has been producing intravenous (IV) artesunate for patients with severe malaria since 1987. But without WHO prequalification or stringent regulatory approval, it could not be purchased by international organizations or donor funds. (2011)

  • Nettie Dzabala, College of Medicine, Malawi

    The College of Medicine is an academic centre of excellence, responsive to the health needs of Malawi by training professionals, providing clinical services and medical research. MMV worked with the college to analyze the antimalarial medicines market in six districts. (2011)

  • Prof. Jonathan Vennerstrom, Prof. Susan Charman & Dr Sergio Wittlin

    The success of the OZ439 project can be attributed to the commitment, enthusiasm and range of scientific expertise of its partners from across the globe. Today, OZ439 is on track to potentially replace artemisinin and become a part of the much-needed one-dose cure for malaria. (2011)

  • Dr Thierry Diagana, Novartis Institue for Tropical Diseases, Singapore

    NITD is working in close collaboration with MMV to explore new drug discovery approaches for malaria. NITD609, if proven to be well tolerated, will be the first antimalarial not belonging to either the artemisinin or peroxide class to enter clinical efficacy studies in recent years. (2010)

  • Prof. Robert Sinden, Imperial College, London, UK

    Current medicines mostly kill the malaria parasite at the blood stage, but to eradicate malaria, we need to stop the parasite being passed on to the next person via mosquitos. Imperial College London has been working with MMV to turn basic biology into knowledge to underpin the development of new antimalarials. (2010)

  • Dr Jörg Möhrle, Head of Translational Medicine, MMV

    OZ439 is a fully synthetic peroxide on track to provide not only a single-dose cure for malaria, but also a potential alternative to currently used artemisinin derivatives. Dr Jörg Möhrle explains this molecule. (2010)

  • Shin Poong Pharmaceutical, South Korea

    MMV and Shin Poong have worked together since 1999 to develop Pyramax®. This new once daily, 3-day treatment for uncomplicated P. falciparum and blood stage P. vivax malaria in infants, children and adults is awaiting regulatory approval by the European Medicines Agency. (2010)

  • Mr. Yu, President of Guilin Pharmaceutical, Mr. Long, Head of the Guilin office of the State Food and Drug Administration, Mr. Wu, Vice Mayor of Guilin City, responsible for Health and Education

    Guilin Pharmaceutical has been producing injectable artesunate for patients with severe malaria since 1987. But without WHO prequalification or stringent regulatory approval, it could not be purchased by international organizations or donor funds and was thus not reaching this vulnerable group. This interview discusses the MMV-Guilin partnership, leading to Guilin Pharmaceutical becoming the first WHO prequalified pharmaceutical company worldwide to produce artesunate for injection. (2010)

  • Dr Arjen Dondorp, Deputy Director and Head of Malaria Research,Mahidol–Oxford Tropical Medi-cine Research Unit, Bangkok, Thailand

    MMV is using its R&D know-how, working with Guilin Pharmaceutical to achieve WHO prequalification for injectale artesunate, treatment for severe malaria. Dr Arjen Dondorp, speaks about treating patients with of severe malaria. (2010)

  • Dr Meg Phillips, University of Texas Southwestern, USA

    MMV Project of the Year award - 2010The enzyme DHODH is one the hottest malaria drug targets under investigation today. This project was awarded MMV’s 2010 Project of the Year in recognition of its impressive progress to rapidly bring these inhibitors towards clinical testing. (2010)

  • Dr Neena Valecha, The National Institute of Malaria Research, India

    NIMR is India’s premier malaria research institute, carrying out studies on drug resistance, and Phase II/ III trials of new drugs. Conducting clinical trials in India is a challenge but MMV and NIMR have had a successful partnership. (2009)

  • Prof. Bruno Gryseels & Prof. Umberto D’Alessandro, ITM, Belgium

    ITM provides postgraduate training for medical doctors and paramedics – a number of whom are headed for central Africa. Collaboration between MMV and ITM focuses on the development and trial of new antimalarials. (2010)

Quick links

  • Ian Bathurst Global Health Travel Award Interviews
Array ( [0] => front_not [1] => site_english [2] => page_all-interviews [3] => view_rhs-column [4] => force_sidebars [5] => node_landing-pages_not [6] => node_page [7] => submenu [8] => view_related [9] => view_rhs-column-below [10] => breadcrumb [11] => internal_adverts_desktop [12] => sitewide_desktop [13] => superfish_menu_desktop )